Pharmacokinetic modeling and simulation to understand diamorphine dose-response in neonates, children, and adolescents
- PMID: 35212432
- DOI: 10.1111/pan.14425
Pharmacokinetic modeling and simulation to understand diamorphine dose-response in neonates, children, and adolescents
Erratum in
-
Corrigendum to: Pharmacokinetic modeling and simulation to understand diamorphine dose-response in neonates, children, and adolescents.Paediatr Anaesth. 2024 Jan;34(1):96. doi: 10.1111/pan.14771. Epub 2023 Sep 29. Paediatr Anaesth. 2024. PMID: 37772454 No abstract available.
Abstract
Pharmacokinetic-pharmacodynamic modeling and simulation can facilitate understanding and prediction of exposure-response relationships in children with acute or chronic pain. The pharmacokinetics of diamorphine (diacetylmorphine, heroin), a strong opioid, remain poorly quantified in children and dose is often guided by clinical acumen. This tutorial demonstrates how a model to describe intranasal and intravenous diamorphine pharmacokinetics can be fashioned from a model for diamorphine disposition in adults and a model describing morphine disposition in children. Allometric scaling and maturation models were applied to clearances and volumes to account for differences in size and age between children and adults. The utility of modeling and simulation to gain insight into the analgesic exposure-response relationship is demonstrated. The model explains reported observations, can be used for interrogation, interpolated to determine equianalgesia and inform future clinical studies. Simulation was used to illustrate how diamorphine is rapidly metabolized to morphine via its active metabolite 6-monoacetylmorphine, which mediates an early dopaminergic response accountable for early euphoria. Morphine formation is then responsible for the slower, prolonged analgesic response. Time-concentration profiles of diamorphine and its metabolites reflected disposition changes with age and were used to describe intravenous and intranasal dosing regimens. These indicated that morphine exposure in children after intranasal diamorphine 0.1 mg.kg-1 was similar to that after intranasal diamorphine 5 mg in adults. A target concentration of morphine 30 μg.L-1 can be achieved by a diamorphine intravenous infusion in neonates 14 μg.kg-1 .h-1 , in a 5-year-old child 42 μg.kg-1 .h-1 and in an 15 year-old-adolescent 33 μg.kg-1 .h-1 .
Keywords: analgesia; children; diacetylmorphine; equianalgesia; heroin; opioids; pharmacokinetics.
© 2022 John Wiley & Sons Ltd.
Similar articles
-
Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain.CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):435-447. doi: 10.1002/psp4.13186. Epub 2025 Feb 13. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 39949065 Free PMC article.
-
Diamorphine pharmacokinetics and conversion factor estimates for intranasal diamorphine in paediatric breakthrough pain:systematic review.BMJ Support Palliat Care. 2024 Jan 8;13(e3):e485-e493. doi: 10.1136/bmjspcare-2021-003461. BMJ Support Palliat Care. 2024. PMID: 35184039
-
Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children.Arch Dis Child. 2009 Dec;94(12):974-8. doi: 10.1136/adc.2008.140194. Epub 2009 Sep 29. Arch Dis Child. 2009. PMID: 19793724 Clinical Trial.
-
Intranasal diamorphine as an alternative to intramuscular morphine: pharmacokinetic and pharmacodynamic aspects.Clin Pharmacokinet. 2003;42(6):501-13. doi: 10.2165/00003088-200342060-00001. Clin Pharmacokinet. 2003. PMID: 12793836
-
Recommended use of morphine in neonates, infants and children based on a literature review: Part 2--Clinical use.Paediatr Anaesth. 1997;7(2):93-101. doi: 10.1111/j.1460-9592.1997.tb00488.x. Paediatr Anaesth. 1997. PMID: 9188108 Review.
Cited by
-
Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice.J Clin Med. 2022 May 26;11(11):3009. doi: 10.3390/jcm11113009. J Clin Med. 2022. PMID: 35683399 Free PMC article. Review.
-
Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain.CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):435-447. doi: 10.1002/psp4.13186. Epub 2025 Feb 13. CPT Pharmacometrics Syst Pharmacol. 2025. PMID: 39949065 Free PMC article.
-
Pharmacokinetic pharmacodynamic modeling of analgesics and sedatives in children.Paediatr Anaesth. 2023 Oct;33(10):781-792. doi: 10.1111/pan.14712. Epub 2023 Jun 21. Paediatr Anaesth. 2023. PMID: 37341161 Free PMC article. Review.
References
REFERENCES
-
- Friedrichsdorf SJ, Postier A. Management of breakthrough pain in children with cancer. J Pain Res. 2014;7:117-123.
-
- Gossop M, Keaney F, Sharma P, Jackson M. The unique role of diamorphine in British medical practice: a survey of general practitioners and hospital doctors. Eur Addict Res. 2005;11:76-82.
-
- Strang J, Groshkova T, Uchtenhagen A, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207:5-14.
-
- Yang SY. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today. 2010;15:444-450.
-
- Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science. 1972;178:984-986.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources